{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:22:46Z","timestamp":1794468166689,"version":"4.9.1"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1097\/01.jcp.0000150227.61501.00","type":"journal-article","created":{"date-parts":[[2005,1,10]],"date-time":"2005-01-10T09:01:31Z","timestamp":1105347691000},"page":"51-58","source":"Crossref","is-referenced-by-count":49,"title":["St. John's Wort Versus Placebo in Social Phobia"],"prefix":"10.1097","volume":"25","author":[{"given":"Kenneth A.","family":"Kobak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie v.H","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rise","family":"Futterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210128","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1001\/archpsyc.1994.03950010008002","article-title":"Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the national comorbidity survey.","volume":"51","author":"Kessler","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"R2-9-20210128","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/archpsyc.1992.01820040034004","article-title":"Social phobia: comorbidity and morbidity in an epidemiologic sample.","volume":"49","author":"Schneier","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"R3-9-20210128","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/(SICI)1520-6394(1996)4:3<126::AID-DA5>3.0.CO;2-E","article-title":"Quality of life in social phobia.","volume":"4","author":"Safren","year":"1996","journal-title":"Depress Anxiety"},{"issue":"suppl 5","key":"R4-9-20210128","first-page":"18","article-title":"Social phobia: a pharmacologic treatment overview.","volume":"56","author":"Jefferson","year":"1995","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"R5-9-20210128","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1176\/ajp.152.9.1368","article-title":"Sertraline for social phobia: a double-blind, placebo-controlled crossover study.","volume":"152","author":"Katzelnick","year":"1995","journal-title":"Am J Psychiatry"},{"issue":"suppl 5","key":"R6-9-20210128","first-page":"232","article-title":"Sertraline treatment of social phobia: a 20-week, double-blind, placebo-controlled study.","volume":"9","author":"Van Ameringen","year":"1999","journal-title":"Eur Neuropsychopharmacol"},{"key":"R8-9-20210128","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.280.8.708","article-title":"Paraxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.","volume":"280","author":"Stein","year":"1998","journal-title":"JAMA"},{"issue":"5","key":"R10-9-20210128","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1176\/ajp.156.5.756","article-title":"Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study.","volume":"156","author":"Stein","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R11-9-20210128","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF02244762","article-title":"Psychopharmacological treatment of social phobia: a double blind placebo controlled study with fluvoxamine.","volume":"115","author":"Van Vliet","year":"1994","journal-title":"Psychopharmacology"},{"issue":"3","key":"R13-9-20210128","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00004714-200206000-00005","article-title":"Fluoxetine in social phobia: a double blind, placebo-controlled pilot study.","volume":"22","author":"Kobak","year":"2002","journal-title":"J Clin Psychopharmacol"},{"issue":"suppl 17","key":"R15-9-20210128","first-page":"54","article-title":"W. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety.","volume":"59","author":"Ballenger","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"R16-9-20210128","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3928\/0048-5713-19980201-10","article-title":"Rethinking side effects of the selective serotonin reuptake inhibitors: sexual dysfunction and weight gain.","volume":"28","author":"Sussman","year":"1998","journal-title":"Psychiatr Ann"},{"issue":"3","key":"R17-9-20210128","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1177\/0269881198012003041","article-title":"Selective serotonin reuptake inhibitors in the treatment of affective disorders: III. Tolerability, safety, pharmacoeconomics.","volume":"12","author":"Goldstein","year":"1998","journal-title":"J Psychopharmacol"},{"issue":"5","key":"R19-9-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0270-6644(05)70324-6","article-title":"Long-term side effects surface with SSRIs.","volume":"26","author":"Sherman","year":"1998","journal-title":"Clin Psychiatry News"},{"issue":"3","key":"R20-9-20210128","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/00926239708403923","article-title":"SSRI-induced sexual dysfunction: fluoxetine, paroxetine, setraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients.","volume":"23","author":"Montego-Gonzalez","year":"1997","journal-title":"J Marit Ther"},{"key":"R21-9-20210128","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/09540268909110417","article-title":"Computer-administered behavior therapies.","volume":"1","author":"Greist","year":"1989","journal-title":"Int Rev Psychiatry"},{"issue":"11","key":"R22-9-20210128","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1176\/ajp.156.11.1819","article-title":"Psychosocial treatment prescriptions for generalized anxiety disorder, panic disorder, and social phobia, 1991-1996.","volume":"156","author":"Goisman","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R23-9-20210128","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1177\/089198879400701s10","article-title":"Benefits and risks of the hypericum extract: drug monitoring study with 3250 patients.","volume":"7","author":"Woelk","year":"1994","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"7052","key":"R24-9-20210128","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.313.7052.253","article-title":"St John's wort for depression-an overview and meta-analysis of randomised clinical trials.","volume":"313","author":"Linde","year":"1996","journal-title":"BMJ"},{"key":"R25-9-20210128","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2165\/00023210-199809060-00004","article-title":"Noncompliance with medication for psychiatric disorders: reasons and remedies.","volume":"6","author":"Breen","year":"1998","journal-title":"CNS Drugs"},{"issue":"8","key":"R26-9-20210128","doi-asserted-by":"crossref","first-page":"727","DOI":"10.4088\/JCP.v63n0811","article-title":"Antidepressant medication management and Health Plan Employer Data Information Set (HEDIS) criteria: reasons for nonadherence.","volume":"63","author":"Kobak","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"R27-9-20210128","first-page":"505","article-title":"Psychiatric pharmacotherapy of depression: treatment guidelines vs reality.","volume":"33","author":"Clagnaz","year":"1997","journal-title":"Psychopharmacol Bull"},{"issue":"4","key":"R28-9-20210128","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1017\/S0033291700049047","article-title":"The treatment of depression in general practice: a comparison of L-tryptophan, amitriptyline, and a combination of L-tryptophan and amitriptyline with placebo.","volume":"12","author":"Thomson","year":"1982","journal-title":"Psychol Med"},{"key":"R29-9-20210128","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-199201000-00007","article-title":"Adequacy and duration of antidepressant treatment in primary care.","volume":"30","author":"Katon","year":"1992","journal-title":"Med Care"},{"issue":"18","key":"R30-9-20210128","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jama.280.18.1569","article-title":"Trends in alternative medicine use in the united states, 1990-1997.","volume":"280","author":"Eisenberg","year":"1998","journal-title":"JAMA"},{"key":"R31-9-20210128","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1176\/appi.ajp.158.2.289","article-title":"The use of complementary and alternative therapies to treat anxiety and depression in the United States.","volume":"158","author":"Kessler","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R32-9-20210128","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1176\/appi.ajp.157.4.521","article-title":"Barriers to the treatment of social anxiety.","volume":"157","author":"Olfson","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"19","key":"R33-9-20210128","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1001\/jama.279.19.1548","article-title":"Why patients use alternative medicine: results of a national study.","volume":"279","author":"Astin","year":"1998","journal-title":"JAMA"},{"issue":"11","key":"R34-9-20210128","first-page":"1145","article-title":"Pharmacological profile of hypericum extract effect on serotonin uptake by postsynaptic receptors. Arzneim-Forsh.","volume":"45","author":"Perovic","year":"1995","journal-title":"(Drug Res)"},{"issue":"suppl 2","key":"R35-9-20210128","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1055\/s-2007-979528","article-title":"Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity.","volume":"30","author":"Muller","year":"1997","journal-title":"Pharmacopsychiatry"},{"issue":"suppl","key":"R36-9-20210128","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1055\/s-2007-979529","article-title":"In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract.","volume":"30","author":"Cott","year":"1997","journal-title":"Pharmacopsychiatry"},{"key":"R37-9-20210128","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1001\/jama.285.15.1978","article-title":"Effectiveness of St John's Wort in major depression: a randomized controlled trial.","volume":"285","author":"Shelton","year":"2001","journal-title":"JAMA"},{"issue":"4","key":"R38-9-20210128","first-page":"289","article-title":"Comparison of equivalence between the St. John's Wort extract LoHyp-57 and fluoxetine.","volume":"49","author":"Harrer","year":"1999","journal-title":"Drug Res"},{"issue":"2","key":"R39-9-20210128","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00004850-200015020-00001","article-title":"Equivalence of St. John's Wort extract (Ze117) and fluoxetine: a randomized, controlled study in mild-moderate depression.","volume":"15","author":"Schrader","year":"2000","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"R40-9-20210128","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0149-2918(00)89010-4","article-title":"Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study.","volume":"22","author":"Brenner","year":"2000","journal-title":"Clin Ther"},{"key":"R41-9-20210128","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1176\/appi.ajp.159.8.1361","article-title":"Efficacy of St. Jon's Wort extract WS 5570 in Major Depression: a double-blind, placebo-controlled trial.","volume":"159","author":"Lecrubier","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R42-9-20210128","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1001\/jama.287.14.1807","article-title":"Effect of Hypericum perforatum (St. John's Wort) in major depressive disorder: a randomized controlled trial.","volume":"287","author":"Group","year":"2002","journal-title":"JAMA"},{"key":"R43-9-20210128","doi-asserted-by":"crossref","first-page":"43S","DOI":"10.1097\/00004714-199006001-00009","article-title":"Comorbidity of anxiety and depression.","volume":"10","author":"Cloninger","year":"1990","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"R44-9-20210128","first-page":"380","article-title":"Treatment of social phobia and comorbid disorders.","volume":"56","author":"Rosenbaum","year":"1995","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"R45-9-20210128","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4088\/JCP.v61n0806","article-title":"An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorder.","volume":"61","author":"Taylor","year":"2000","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"R46-9-20210128","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/01.jcp.0000088921.02635.13","article-title":"St. John's Wort in generalized anxiety disorder: three more case reports.","volume":"23","author":"Kobak","year":"2003","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"R47-9-20210128","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00004714-200112000-00026","article-title":"St. John's Wort in generalized anxiety disorder: three case reports.","volume":"21","author":"Davidson","year":"2001","journal-title":"J Clin Psychopharmacol"},{"issue":"suppl 4","key":"R48-9-20210128","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1078\/1433-187X-00305","article-title":"Treating depression comorbid with anxiety-results of an open, practice-oriented study with St John's wort WS 5572 and valerian extract in high doses.","volume":"10","author":"Muller","year":"2003","journal-title":"Phytomedicine"},{"key":"R49-9-20210128","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression.","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R50-9-20210128","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1016\/S0140-6736(99)00418-3","article-title":"Second thoughts about safety of St John's wort.","volume":"354","author":"Ernst","year":"1999","journal-title":"Lancet"},{"key":"R51-9-20210128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000414022","article-title":"Social phobia.","volume":"22","author":"Liebowitz","year":"1987","journal-title":"Mod Probl Pharmacopsychiatry"},{"key":"R52-9-20210128","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1037\/1040-3590.7.4.472","article-title":"Reliability and validity of the Hamilton Depression Inventory: a paper-and-pencil version of the Hamilton Depression Rating Scale Clinical Interview.","volume":"7","author":"Reynolds","year":"1995","journal-title":"Psychol Assess"},{"issue":"suppl","key":"R54-9-20210128","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1055\/s-2007-979341","article-title":"Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract.","volume":"31","author":"Muller","year":"1998","journal-title":"Pharmacopsychiatria"},{"key":"R55-9-20210128","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-2007-979340","article-title":"Antidepressant activity of hypericum perforatum and hypesforin: the neglected possibility.","volume":"31","author":"Chatterjee","year":"1998","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"R56-9-20210128","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0024-3205(98)00299-9","article-title":"Hyperforin as a possible antidepressant component of hypericum extracts.","volume":"63","author":"Chatterjee","year":"1998","journal-title":"Life Sci"},{"issue":"4","key":"R59-9-20210128","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00004714-199708000-00003","article-title":"Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study.","volume":"17","author":"Lott","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"R60-9-20210128","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1600-0447.1995.tb09596.x","article-title":"Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine.","volume":"92","author":"Fahlen","year":"1995","journal-title":"Acta Psychiatr Scand"},{"key":"R61-9-20210128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0924-977X(92)90032-4","article-title":"Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor.","volume":"2","author":"Van Vliet","year":"1992","journal-title":"Eur Neuropsychopharmacol"},{"key":"R62-9-20210128","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1192\/bjp.161.3.353","article-title":"Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine.","volume":"161","author":"Versiani","year":"1992","journal-title":"Br J Psychiatry"},{"key":"R63-9-20210128","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1192\/bjp.172.1.70","article-title":"Placebo-controlled trial of moclobemide in social phobia.","volume":"172","author":"Schneier","year":"1998","journal-title":"Br J Psychiatry"},{"issue":"2","key":"R64-9-20210128","first-page":"71","article-title":"The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study.","volume":"247","author":"Katsching","year":"1997","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"4","key":"R65-9-20210128","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00004714-199708000-00002","article-title":"Moclobemide in social phobia: a controlled dose-response trial.","volume":"17","author":"Noyes","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"R66-9-20210128","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00004714-199312000-00008","article-title":"Treatment of social phobia with clonazepam and placebo.","volume":"13","author":"Davidson","year":"1993","journal-title":"J Clin Psychopharmacol"},{"key":"R67-9-20210128","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/archpsyc.49.4.290","article-title":"Phenelzine vs atenolol in social phobia: a placebo-controlled comparison.","volume":"49","author":"Liebowitz","year":"1992","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"R68-9-20210128","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00004714-199908000-00010","article-title":"Treatment of social phobia with gabapentin: a placebo-controlled study.","volume":"19","author":"Pande","year":"1999","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"R72-9-20210128","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00004714-200206000-00005","article-title":"Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study.","volume":"22","author":"Kobak","year":"2002","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"R73-9-20210128","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.jcp.0000104906.75206.8b","article-title":"A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder.","volume":"24","author":"Westenberg","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"R74-9-20210128","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1192\/bjp.175.2.120","article-title":"Paroxetine in social phoiba\/social anxiety disorder (randomised, double-blind, placebo-controlled study).","volume":"175","author":"Baldwin","year":"1999","journal-title":"Br J Psychiatry"},{"issue":"suppl 1","key":"R75-9-20210128","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0165-0327(98)00093-7","article-title":"Implications of the severity of social phobia.","volume":"50","author":"Montgomery","year":"1998","journal-title":"J Affect Disord"},{"issue":"2","key":"R76-9-20210128","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4088\/JCP.v63n0211","article-title":"Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials.","volume":"63","author":"Stein","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R77-9-20210128","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4088\/JCP.v64n0708","article-title":"Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study.","volume":"64","author":"Liebowtiz","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"R78-9-20210128","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00004714-200202000-00007","article-title":"Severity of depression and response to antidepressants and placebo: an analysis of the food and drug administration database.","volume":"22","author":"Khan","year":"2002","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"R79-9-20210128","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00004714-200012000-00001","article-title":"Concerns about clinical drug trials.","volume":"20","author":"Robinson","year":"2000","journal-title":"J Clin Psychopharmacol"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00130478-200501000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T13:16:57Z","timestamp":1682947017000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-200502000-00009"}},"subtitle":["Results From a Placebo-Controlled Pilot Study"],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jcp.0000150227.61501.00","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2005,2]]}}}